Previous studies have showed that the glutamine levels are lower in the brains of patients with Alzheimer's disease (AD), and the glutamine supplementation could reduce inflammation-induced neuronal cell cycle activation, tau phosphorylation, and ATM-activation in a mouse model of AD [10]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.